The secretome of mesenchymal stem cells derived from the placenta and its secretions in the treatment of catheter infection in hemodialysis patients

Phase 3

• Conditions: End-stage renal disease patients under more than six month of hemodialysis treatment and diagnosis of permanent catheter infection.; End stage renal disease; N18.6

• Registration Number: IRCT20201108049311N8
• Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 6 March 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Patients with end-stage kidney disease under hemodialysis for at least six month and permanent catheter infection with diagnosis of blood culture and clinical symptoms
Age between 18 and 80 years
Willingness to participate in the study
Under hemodialysis for two or three times a week

Exclusion Criteria

Having symptoms of severe sepsis such as decreased level of consciousness and low blood pressure
Having a temporary catheter
Having symptoms of acute thromboembolism

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Incidence of infection. Timepoint: 15 days after the beginning of the intervention. Method of measurement: Checking the occurrence of ague (body temperature above 37 °C).;The presence of suppuration and redness in the catheter site. Timepoint: 15 days after the beginning of the intervention. Method of measurement: Observationally.